These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3577186)

  • 1. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tubercular prostatic abscess following intravesical Bacillus Calmette-Guerin therapy].
    Hashimura M; Momose H; Takenaga M; Hoshiyama H; Fujimoto K; Ono T; Oyama N
    Hinyokika Kiyo; 2012 Mar; 58(3):169-72. PubMed ID: 22495047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
    Enatsu N; Ota T; Ochi A
    Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
    [No Abstract]   [Full Text] [Related]  

  • 5. [Invasive bladder cancer with concomitant carcinoma in situ treated with chemoradiotherapy followed by BCG intravesical infusion therapy to preserve the bladder : report of three cases].
    Ohzeki T; Hashimoto K; Katoh Y; Iguchi M
    Hinyokika Kiyo; 2011 Oct; 57(10):581-4. PubMed ID: 22089159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary tuberculosis of glans penis after intravesical Bacillus Calmette Guerin immunotherapy.
    Sharma VK; Sethy PK; Dogra PN; Singh U; Das P
    Indian J Dermatol Venereol Leprol; 2011; 77(1):47-50. PubMed ID: 21220879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
    Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
    Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive arthritis after the intravesical instillation of BCG.
    Macía Villa C; Sifuentes Giraldo W; Boteanu A; González Lanza M; Bachiller Corral J
    Reumatol Clin; 2012; 8(5):284-6. PubMed ID: 22377450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
    Kamat AM; Willis DL; Dickstein RJ; Anderson R; Nogueras-González G; Katz RL; Wu X; Barton Grossman H; Dinney CP
    BJU Int; 2016 May; 117(5):754-60. PubMed ID: 26032953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
    Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
    De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
    Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
    Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.
    Alexandroff AB; Nicholson S; Patel PM; Jackson AM
    Immunotherapy; 2010 Jul; 2(4):551-60. PubMed ID: 20636008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal tuberculosis with severe neurological symptoms as a complication of intravesical BCG therapy for carcinoma of the bladder.
    Białecki J; Nowak-Misiak M; Rąpała K; Marczyński W; Suchodolski G; Truszczyńska A
    Neurol Neurochir Pol; 2016; 50(2):131-8. PubMed ID: 26969570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.
    Kamat AM; Flaig TW; Grossman HB; Konety B; Lamm D; O'Donnell MA; Uchio E; Efstathiou JA; Taylor JA
    Nat Rev Urol; 2015 Apr; 12(4):225-35. PubMed ID: 25800393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
    Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
    Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.
    Brincks EL; Risk MC; Griffith TS
    Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Henoch Schönlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy.
    Tsukada H; Miyakawa H
    Intern Med; 2017; 56(5):541-544. PubMed ID: 28250302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer.
    Soria F; Giordano A; Shariat SF; Gontero P
    Curr Opin Urol; 2020 Jul; 30(4):542-546. PubMed ID: 32427633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of primary versus secondary bladder carcinoma in situ.
    Chade DC; Shariat SF; Adamy A; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2010 Aug; 184(2):464-9. PubMed ID: 20620399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.